BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37222437)

  • 1. Adjuvant Chemotherapy and Effect on Long-Term Survival in Ampullary Adenocarcinoma: A Multicenter Cohort Study.
    Shin DW; Lee JM; Lee JC; Lee HS; Yoon SB; Jang DK; Park JK; Jung MK; Lee YS; Hwang JH
    J Am Coll Surg; 2023 Sep; 237(3):501-512. PubMed ID: 37222437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
    Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
    Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversial benefit of 5-fluorouracil/leucovorin-based adjuvant chemotherapy for ampullary cancer: a propensity score-matched analysis.
    Kang J; Lee W; Shin J; Park Y; Kwon JW; Jun E; Song KB; Lee JH; Hwang DW; Park SY; Kim SC
    Langenbecks Arch Surg; 2022 May; 407(3):1091-1097. PubMed ID: 35013798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients.
    Kim JH; Jeong JH; Ryoo BY; Kim KP; Chang HM; Oh D; Song TJ; Lee SS; Seo DW; Lee SK; Kim MH; Park Y; Kwon JW; Hwang DW; Lee JH; Lee W; Kim SC; Yoo C; Song KB
    Cancer Res Treat; 2021 Apr; 53(2):424-435. PubMed ID: 33171024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the role of adjuvant external beam radiotherapy on resected adenocarcinoma of the ampulla of vater.
    Miura JT; Jayakrishnan TT; Amini A; Johnston FM; Tsai S; Erickson B; Quebbeman EJ; Christians KK; Evans DB; Gamblin TC; Turaga KK
    J Gastrointest Surg; 2014 Nov; 18(11):2003-8. PubMed ID: 25159502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic outcomes in resected ampullary cancer: Relevance of histologic subtype and adjuvant chemotherapy.
    Affi Koprowski M; Sutton TL; Brinkerhoff BT; Grossberg A; Sheppard BC; Mayo SC
    Am J Surg; 2021 Jun; 221(6):1128-1134. PubMed ID: 33883071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
    Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
    JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
    Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
    Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy.
    Sugawara T; Rodriguez Franco S; Sherman S; Kirsch MJ; Colborn K; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Schulick RD; Del Chiaro M
    JAMA Oncol; 2023 Mar; 9(3):316-323. PubMed ID: 36480190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of endoscopic papillectomy for ampullary adenoma with high-grade dysplasia or adenocarcinoma: a propensity score-matched analysis.
    Yoon SB; Jung MK; Lee YS; Park JK; Jang DK; Lee JM; Lee HS; Shin DW; Lee JC; Hwang JH
    Surg Endosc; 2023 May; 37(5):3522-3530. PubMed ID: 36587061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathologic Predictors of Survival and Recurrence in Resected Ampullary Adenocarcinoma: International Multicenter Cohort Study.
    Moekotte AL; Lof S; Van Roessel S; Fontana M; Dreyer S; Shablak A; Casciani F; Mavroeidis VK; Robinson S; Khalil K; Gradinariu G; Mowbray N; Al-Sarireh B; Fusai GK; Roberts K; White S; Soonawalla Z; Jamieson NB; Salvia R; Besselink MG; Abu Hilal M
    Ann Surg; 2020 Dec; 272(6):1086-1093. PubMed ID: 30628913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Benefit of Adjuvant Chemotherapy After Pancreatoduodenectomy for Ampullary Adenocarcinoma: a Propensity-Matched National Cancer Database (NCDB) Analysis.
    Kamarajah SK; Bednar F; Cho CS; Nathan H
    J Gastrointest Surg; 2021 Jul; 25(7):1805-1814. PubMed ID: 33230687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort.
    Bergeat D; Turrini O; Courtin-Tanguy L; Truant S; Darnis B; Delpero JR; Mabrut JY; Regenet N; Sulpice L
    Langenbecks Arch Surg; 2018 Sep; 403(6):701-709. PubMed ID: 30112638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas - are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?
    Ramaswamy A; Bhandare M; Bal M; Shrirangwar S; Kataria P; Majumdar S; Swami R; Rohila J; Chaudhari V; Mandavkar S; Chavan N; Shrikhande SV; Ostwal V
    HPB (Oxford); 2020 Mar; 22(3):376-382. PubMed ID: 31405778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
    Krishnan S; Rana V; Evans DB; Varadhachary G; Das P; Bhatia S; Delclos ME; Janjan NA; Wolff RA; Crane CH; Pisters PW
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):735-43. PubMed ID: 17980502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    Neoptolemos JP; Moore MJ; Cox TF; Valle JW; Palmer DH; McDonald AC; Carter R; Tebbutt NC; Dervenis C; Smith D; Glimelius B; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Ghaneh P; Halloran CM; Lerch MM; Oláh A; Rawcliffe CL; Verbeke CS; Campbell F; Büchler MW;
    JAMA; 2012 Jul; 308(2):147-56. PubMed ID: 22782416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy.
    Shroff S; Overman MJ; Rashid A; Shroff RT; Wang H; Chatterjee D; Katz MH; Lee JE; Wolff RA; Abbruzzese JL; Fleming JB; Wang H
    Arch Pathol Lab Med; 2013 Nov; 137(11):1619-26. PubMed ID: 24168499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of radiotherapy in patients with resected ampullary carcinoma: findings based on the SEER database.
    Zhao W; Wang B; Zhao A; Tian Q; Zhang L; Wang L; Zhao X; Yang J; Dong D
    HPB (Oxford); 2019 Nov; 21(11):1535-1540. PubMed ID: 31056288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant radiotherapy following pancreaticoduodenectomy for ampullary adenocarcinoma improves survival in node-positive patients: a propensity score analysis.
    Kamarajah SK
    Clin Transl Oncol; 2018 Sep; 20(9):1212-1218. PubMed ID: 29497964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical treatment of duodenal adenocarcinoma: ampullary vs. non-ampullary, short- and long-term outcomes.
    Tesarikova J; Skalicky P; Kurfurstova D; Svebisova H; Urban O; Falt P; Zapletalova J; Klos D; Lovecek M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):290-296. PubMed ID: 34012147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.